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Background
Postpartum haemorrhage (PPH) is one of the most common 
obstetric emergencies and is a leading cause of maternal mortality 
world-wide1. Most of the deaths are in low and middle-income 
countries and most deaths occur soon after childbirth2. Severe 
postpartum bleeding can sometimes be managed by the administra-
tion of oxytocin and other uterotonic drugs3. However, if uterotonics 
fail to control the bleeding, surgical intervention may be required.
Tranexamic acid reduces bleeding by inhibiting the enzymatic 
breakdown of fibrin blood clots by plasmin4. A systematic review of 
clinical trials of tranexamic acid in surgery showed that it reduces 
blood loss by about one-third5,6. Tranexamic acid also reduces 
mortality in bleeding trauma patients. When given within three 
hours of injury, tranexamic acid reduces the risk of death due to 
bleeding by approximately one-third7. Early activation of fibrinoly-
sis is common after trauma and worsens bleeding8. Trauma triggers 
the release of tissue plasminogen activator (TPA), the enzyme that 
converts plasminogen to plasmin and the resulting fibrinolysis plays 
a key role in the pathogenesis of trauma induced coagulopathy. 
Early administration of tranexamic acid in bleeding trauma patients 
inhibits fibrinolysis and prevents coagulopathy9.
Increased fibrinolytic activity is also observed after childbirth10. 
Within 1 hour of delivery, the serum concentration of TPA dou-
bles, possibly due to the trauma of childbirth10. Active PPH is 
associated with an early increase in D-dimers and plasmin-anti- 
plasmin complexes11. A randomised trial conducted in obstet-
ric centres in France found that the increase in D-dimers can be 
inhibited by tranexamic acid administration11. To examine the 
effect of tranexamic acid on fibrinolysis and coagulation in women 
at high risk of death after PPH, we aim to conduct a randomised 
double blind placebo controlled trial in Ibadan, Nigeria (World 
Maternal Antifibrinolytic Trial-Effect of Tranexamic Acid on 
Coagulation [WOMAN-ETAC]). 
Methods
Hypothesis: We hypothesise that tranexamic acid will reduce 
death due to bleeding in women with PPH by inhibiting the 
breakdown of fibrin clots thus preventing or reducing the severity 
of coagulopathy. Therefore, our primary aim is to determine the 
effects of tranexamic acid on indicators of fibrinolysis and our 
secondary aim is to determine the effect of tranexamic acid on 
coagulation. 
Design: A randomised double blind placebo controlled trial will 
be conducted as a sub-study within the WOMAN trial (Figure 1). 
The aims and methods of the WOMAN trial are described in detail 
elsewhere12,13. Briefly, adult women with clinically diagnosed 
primary PPH after vaginal or caesarean delivery are eligible for 
inclusion. After the appropriate consent procedure has been fol-
lowed, each patient is randomly allocated to receive 1 gram of 
tranexamic acid or matching placebo by intravenous injection. 
If bleeding continues after 30 minutes, or if bleeding stops and 
restarts within 24 h, a second dose of 1 g of tranexamic acid or 
placebo may be given. The trial will be conducted in accordance 
with versions 1 and 1.1 of the protocol.
To examine the effect of tranexamic acid on fibrinolysis and 
coagulation, in a sample of trial participants we will collect 
blood at baseline and 30 minutes after the first dose of tranexamic 
acid or matching placebo. Our primary objective is to evalu-
ate the effect of tranexamic acid on fibrinolysis. Fibrinolysis will 
be assessed by measuring D-dimers and by rotational thromboe-
lastometry (ROTEM). Secondary outcomes will be international 
normalized ratio (INR), prothrombin time (PT), activated partial 
thromboplastin time (APTT), fibrinogen, haemoglobin and plate-
lets. We aim to include about 180 women from the University 
College Hospital, Ibadan in Nigeria.
Number of patients needed: We assume that D-dimer mean and 
standard deviation in the control group will be 9,000 ng/mL and 
7,200 ng/mL respectively. Taking into account that we would adjust 
for baseline measurement and assuming a correlation between 
baseline and follow-up of 0.4, we estimate that a study with about 
180 patients would have 90% power (two sided alpha=5%) to detect 
a reduction of 30% in the mean D-dimer value in the tranexamic 
group. 
a) Blood sample collection: Immediately after we randomise a 
WOMAN trial participant but prior to giving the trial treatment, 
approximately 15 mL of venous blood will be drawn:
•    Two 5 mL samples collected in 5mL vacutainer tubes 
containing 0.5 mL sodium citrate (0.109mol/L) for coagula-
tion tests and thromboelastometry.
•    One 5 mL sample in a 5 mL vacutainer tube containing 
EDTA.K3 for full blood count analysis.
Once the sample is collected, we will give the first dose of the 
WOMAN trial treatment according to the WOMAN trial protocol. 
Approximately 30 (± 15) minutes after administration of the first 
dose of treatment, we will collect a second blood sample in the 
same way.
b) Blood sample analysis: We will measure D-dimers, INR, PT, 
APTT and fibrinogen using the HumaClot Junior automated 
coagulation analyser (Human, GmBH, Germany). We will centri-
fuge the blood sample at 3000 g for 20 minutes before analysis. We 
will measure thromboelastometry parameters at 37°C using two of 
the four channels (EXTEM, APTEM) on the ROTEM coagulation 
analyser [TEM®, Munich, Germany]). The EXTEM test activates 
haemostasis by adding tissue factor. The result is influenced by 
extrinsic coagulation factors, platelets and fibrinogen. EXTEM is a 
screening test for the (extrinsic) haemostasis system. The APTEM 
test is an EXTEM based assay in which fibrinolysis is inhibited 
with aprotinin. A substantial improvement in clot parameters in 
APTEM compared to EXTEM suggests fibrinolysis. We will obtain 
a full blood count using a five parameter particle counter Sysmex 
KN analyser (Sysmex Corporation, Kobe, Japan).
c) Quality control: We will store ROTEM reagents in a refrigerator 
at 2–8°C and will monitor the temperature on a temperature moni-
toring log. Once opened, ROTEM® reagents have a limited shelf life 
(EXTEM, 8 days after opening; APTEM, 14 days after opening). 
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Figure 1. Study overview.
After opening a new bottle of reagent, we will write the expiry 
date of the reagent on the label. We will not use out of date rea-
gents. We will conduct routine quality control (QC) analyses in 
accordance with the trial’s standard operating procedures. Only 
trained personnel will make ROTEM measurements. TEM Inno-
vations GmbH staff will train key personnel before the start of 
the trial. The lead investigator will train new staff members. We 
will store ROTEM data on the machine but will take a back-up 
after each analysis. These will be sent to the Trial Co-ordinating 
Centre in London. Quality Control of the HumaClot Junior (Human, 
Germany) will be as per the manufacturer’s instructions . We will 
file QC reports at the study site so that they are available to the 
trial team, monitors and auditors.
d) Other data collection: We will collect patient entry and outcome 
data as per the WOMAN trial protocol. In addition, we will collect 
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the following information: time of blood samples, time trial treat-
ment is administered, time laboratory analysis started and ended, 
any treatment given that may affect coagulation, adverse events, 
and technical problems with analysis (Supplementary material). 
Any untoward medical occurrence affecting a trial participant up to 
day 42 will be reported in line with the WOMAN trial protocol.
e) Potential risks to participants: The study involves two blood tests 
about 30 minutes apart which may cause pain and bruising at the 
venepuncture site. The results of the routine laboratory tests can 
be used to guide treatment in line with local procedures. However, 
the ROTEM tests will not be used to guide treatment and are for 
research purposes only.
(f) Roles and responsibilities: The WOMAN-ETAC trial is spon-
sored by the London School of Hygiene and Tropical Medicine. 
The Trial Steering Committee (TSC) in place for the WOMAN 
trial and will be informed of this study. Decisions of the TSC may 
impact directly the continuation of the WOMAN-ETAC study. If 
required by the TSC, information about the WOMAN-ETAC study 
will be reported routinely.
Adverse events which are directly associated with the WOMAN-
ETAC study will be reported to the Data Monitoring Committee 
which is in place for the WOMAN trial. Otherwise there will be no 




We will conduct exploratory analyses to examine the associa-
tion between clinical parameters (age, type of delivery, blood loss 
volume, cause of PPH, blood pressure, clinical signs of shock) and 
the presence or absence of coagulopathy as well as the presence or 
absence of “hyperfibrinolysis.” Coagulopathy will be defined as an 
INR >1.2 and A5 ≤ 40mm15,16. Hyperfibrinolysis will be defined as 
ML>15% on ROTEM.
We will report the univariate odds ratios for each clinical parameter. 
All variables will be included in a model to assess multivariate odds 
ratio. Likelihood ratio tests (LRT) will be used to evaluate statisti-
cally if a variable is a risk factor.
Main analysis
We will report participant progress through the trial in a 
Consolidated Standards of Reporting Trials (CONSORT) flow 
diagram (Figure 2). We will report the number of participants 
randomised, allocated to each treatment, lost to follow up or 
excluded from the analysis (e.g. samples for which there were 
technical problems with processing). We will conduct per-protocol 
analysis that include all participants who satisfy the eligibility 
criteria, receive the allocated treatment, have follow up samples 
and at least one measurement of the primary outcome. We will not 
exclude outliers or impute missing data since this would be inap-
propriate in a study aimed at understanding the biological effects 
of tranexamic acid. If the coagulation analyser reports, “no clot 
detected” in lieu of a numeric result, the patient will be excluded 
from quantitative analysis. However, we will report the number of 
patients in whom there was no clot detected.
Baseline data: We will report participant characteristics and 
baseline data as numbers and percentages. We will report means 
and standard deviations for normally distributed parameters and 
medians and interquartile (25% and 75%) ranges for non-normal 
distributions. We will test normality using the Shapiro-Wilk test. 
We will present dichotomous variables as number and percent.
Co-primary outcomes: We will assess the effect of tranexamic 
acid on fibrinolysis by examining d-dimer and maximum clot lysis 
(ML). D-dimer is a sensitive marker of fibrinolysis. ML (EXTEM 
Figure 2. Trial profile.
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ROTEM®) is the percentage reduction after maximum clot forma-
tion (maximum strength of the clot firmness reached during the 
test) at the point of lowest clot amplitude. The time point at which 
ML is calculated varies, since it is calculated at the point of lowest 
clot amplitude during the test after maximum clot formation, which 
varies by participant. EXTEM ML is considered to be one of the 
most sensitive ROTEM® measures of fibrinolysis15. If tranexamic 
acid inhibits fibrinolysis, we would expect to see lower D-dimer 
measurements and ML percentages in the tranexamic acid group 
versus placebo. Where the primary outcomes have non-normal 
distributions, the data will be transformed. We will assume vari-
ances to be equal since study participants are drawn from the same 
population. For each co-primary outcome, we will compare the 
follow up results of each treatment group (t-test), and conduct a 
regression analysis that includes the baseline measure.
Secondary outcomes: We will assess the effect of tranexamic 
acid on coagulopathy by examining a range of thromboelastom-
etry parameters using the follow up samples. These will include 
clotting time (CT), the interval from the start of the test until a 
clot firmness of 2 mm is reached; clot amplitude at 5 (A5) and 
ten minutes (A10); maximum clot firmness (MCF) which is the 
maximum clot amplitude reached during the test. Studies in bleed-
ing trauma patients show that ROTEM A5 is a sensitive indicator 
of coagulopathy. When coagulopathy is defined as an INR >1.2, 
a threshold level of EXTEM A5 ≤ 40 mm has a sensitivity of 
73%16. If tranexamic acid inhibits fibrinolysis and prevents coag-
ulopathy we would expect higher values for clot amplitude A5, 
A10, and MCF in the tranexamic acid group compared to placebo. 
We will also compare the lysis index at 30 (LI30) and 60 minutes 
(LI60). Lysis index measures the ratio of the firmness of a clot at 
a given time point and MCF. We expect LI30, LI60 to be higher 
with tranexamic acid. Additionally, we will assess the difference 
between follow up results of each treatment group in the following 
parameters: INR, PT, APTT, fibrinogen and haemoglobin. We will 
analyse secondary outcomes using t-tests. We will conduct regres-
sion analysis that include the baseline measure. 
Sub-group analyses
Time since delivery: In bleeding trauma patients, the effect of 
tranexamic acid varies according to the interval between injury 
and treatment. The Clinical Randomisation of an Antifibrinolytic 
in Significant Haemorrhage (CRASH)-2 trial showed strong evi-
dence that tranexamic acid reduced the risk of bleeding deaths 
when given within 3 hours of injury but there was no reduction 
in those treated after 3 hours7. Early fibrinolysis is common after 
trauma, and is associated with an increase in mortality. Trauma 
initiates the early release of TPA from storage granules in the vas-
cular endothelium. The release of TPA results in early fibrinolysis 
that exacerbates bleeding8. Temporal changes in fibrinolysis have 
also been observed after childbirth. In the first hour after delivery, 
there is a doubling of the serum concentration of TPA, possibly due 
to the trauma of childbirth. After the first hour the concentration 
of TPA decreases rapidly and by a large amount. At the same time, 
PAI-1 and PAI-2 (plasminogen activator inhibitors) increase around 
delivery and for several days. To examine temporal changes in 
fibrinolytic parameters we will report baseline data stratified 
by time to treatment (≤3 hours after delivery, and >3 hours after 
delivery). We expect fibrinolysis to be more prevalent in the first 
three hours. We will also examine the effect of tranexamic acid on 
fibrinolysis stratified by time to treatment.
Type of delivery: Because a substantial proportion of all deliveries 
are by caesarean section and caesarean section is an estab-
lished risk factor for PPH, it is important to examine whether the 
biological effect of tranexamic acid varies by type of delivery. 
Although we hypothesise that the effects of tranexamic acid on 
fibrinolysis and coagulation will be similar to those in trauma 
patients, type of delivery might not accurately reflect the extent to 
which delivery is traumatic. For example, a study in uncomplicated 
pregnancy found that D-dimer levels after instrumental vaginal 
delivery were higher than after spontaneous vaginal birth and 
similar to those after caesarean section17. We do not anticipate 
substantial heterogeneity by type of delivery.
Cause of postpartum haemorrhage: We will examine the effect of 
tranexamic acid by cause of bleeding (uterine atony versus all other 
causes) as determined at baseline. We do not anticipate substantial 
heterogeneity by cause of haemorrhage.
Maternal anaemia: Over fifty million pregnant women are anaemic 
world-wide18. The highest prevalence of maternal anaemia is in 
Africa (57%) and in South-East Asia (48%). Anaemia is a risk 
factor for PPH and venous thromboembolism (VTE)19,20. Given 
the high prevalence of anaemia in Africa and Asia, we will examine 
the effect of tranexamic acid on fibrinolysis and coagulation 
separately in anaemic and non-anaemic women. We will define 
anaemia as a haemoglobin concentration less than 110 g/L.
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